Radient Pharmaceuticals Resumes Collaboration to Advance Its Onko-Sure(R) In Vitro Diagnostic Cancer Test in the USA

31 August 2010, 5:52 am

TUSTIN, CA--(Marketwire - August 31, 2010) - Radient Pharmaceuticals Corporation (RPC) ( NYSE Amex : RPC ) announced today it has resumed collaborations with Mayo Collaborative Services, Inc. to conduct a clinical study for the validation of RPC's US FDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test as a useful tool in colorectal cancer (CRC) recurrence and treatment monitoring.... Read More »

More Topics from "News"

• Vita-Tech International Donates Nutritional Products in Africa
• Company Profile for MDLsolutions, Inc.
• Advanced Feeedback Systems Translate to Lower Costs for Fluid Research Meter, Mix, Dispense ...
• NAFA PSW Chapter to Hold Golf Outing in October
• Peregrine to Report First Quarter Fiscal Year 2011 Financial Results After Market on September 9, 2010
• First day of school for Tustin Unified
• Radient Pharmaceuticals Provides Domestic and International Target Market Details for Its Onko-Sure(R) IVD Cancer ...
• Radient Pharmaceuticals Provides Domestic and International Target Market Details for Its Onko-Sure(R) IVD Cancer ...
• 628-Unit Creekside Meadows Apartments Trades